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Optic neuritis (ON) is an inﬂammatory optic nerve injury, which is strongly associated with multiple sclerosis (MS). Axonal
damage in the optic nerve manifests as retinal nerve ﬁber layer (RNFL) deﬁcits, which can be readily quantiﬁed with optical
coherence tomography (OCT). The RNFL represents the most proximal region of the aﬀerent visual pathway; and, as such, is
a unique region of the central nervous system (CNS) because it lacks myelin. Changes in retinal integrity can be correlated with
reliable and quantiﬁable visual outcomes to provide a structural-functional paradigm of CNS injury. Because the eye provides a
unique “view” into the eﬀects of CNS inﬂammation, the ON “system model” may provide greater understanding about disease
mechanisms,whichunderpin disabilityinMS.Thisreview addressestheapplicationsofOCTinstudy ofONpatients,withspeciﬁc
reference to the published reports to date. The future role of OCT is discussed, both in terms of the potential gains and certain
challenges associated with this evolving technology.
1.OpticNeuritis:AnOverview
Optic neuritis (ON) is an inﬂammatory optic nerve injury,
which causes subacute onset vision loss in children and
young adults. Much of our understanding regarding the
clinical presentation of ON has been derived from the Optic
Neuritis Treatment Trial (ONTT) [1]. This randomized,
placebo-controlled, multicenter trial compared the visual
beneﬁts of treatment with either intravenous methylpred-
nisolone (250mg every 6 hours for 3 days followed by oral
prednisone (1mg/kg per day) for 11 days), oral prednisone
(1mg/kg per day for 14 days), or oral placebo (for 14 days)
in 457 patients with acute ON [1]. From the ONTT, we
learned that most ON patients are young (mean age 32
years) Caucasian (85%) women (77%) [1]. Over ninety
p e r c e n to fO Np a t i e n t sr e p o r tp a i na tt h eo n s e to fv i s i o n
loss [1] which is often characterized as an “ache” made
worse with eye movements. Vision loss is generally acute,
to sub-acute in onset progressing over a period of hours
to days. The severity of vision loss may range from mild
(Snellen equivalent of 20/20 vision) to no light perception
(NLP) [2]. Dyschromatopsia or decreased color vision is
quite common [2], and this ﬁnding can help localize the
diagnosis in patients with relatively mild visual acuity
deﬁcits. Patients with unilateral ON often manifest a relative
aﬀerent pupil defect, unless there is coexisting optic nerve
damage in the contralateral eye [2]. Visual ﬁeld defects in
ON correspond to the topography of the retinal nerve ﬁber
layer (RNFL) and may be arcuate, altitudinal, or cecocentral
in shape. In cases of retrobulbar ON the fundus examination
is initially normal, whereas patients with anterior ON or
“papillitis” may manifest optic disc swelling [2, 3]. Atypical
fundus ﬁndings in ON patients include severe optic disc
edema, peripapillary hemorrhages, or retinal exudates [4].
Clinical features which are not typical of ON should prompt
an investigation for other diagnoses including ischemic,
compressive, inﬁltrative, toxic-metabolic, and inﬂammatory
optic neuropathies.
The majority of ON patients recover vision over a period
of weeks [1–3], during which time optic disc pallor may
evolve as a “footprint” of the previous inﬂammatory injury.
Yet, even in patients who recover 20/20 vision in their2 Multiple Sclerosis International
aﬀected eye, persistent visual problems (fatigue-induced
vision loss; alteredmotion and depthperception;loss ofcon-
trast sensitivity) are common. Patients with previous ON
frequently describe transient vision loss with increased body
temperature, which is known as “Uhthoﬀ’s” phenomenon
[2]. Because axonal damage is an early manifestation in
demyelinating plaques of multiple sclerosis (MS) patients
[5], persistent visual deﬁcits after ON may be a consequence
of prior demyelination and/or permanent axonal damage in
the anterior visual pathway.
2.ExploringtheLinkbetweenOptic
Neuritisand MultipleSclerosis
There is a strong association between ON and MS, such that
approximately 20% of patients experience ON as their initial
demyelinating event, and 30–70% of MS patients develop
ON during the course of their disease [6, 7]. Many patients
who present with ON as a clinically isolated syndrome
(CIS) demonstrate evidence of disseminated central nervous
system (CNS) inﬂammation on their baseline magnetic
resonance imaging (MRI) study (50% to 70%) and harbor
abnormal cerebrospinal ﬂuid (CSF) constituents (60 to
70%), which increase their future risk of MS [2, 4, 8–11].
After 15 years, 72% of patients in the ONTT who had one or
more white matter lesions on their baseline MRI developed
clinically deﬁnite MS (CDMS) as compared to only 25% of
patients with no MRI lesions [10].
3.OpticNeuritis:ASystemModelof
MultipleSclerosis?
Vision loss is both prevalent and relevant in MS patients.
Because the visual system is a functionally eloquent region
of the CNS, patients are apt to notice and seek help for their
symptoms from a health care professional. Therefore, it is
possibletoestablisha deﬁnitetimeofonset ofsymptoms and
follow patients through the acute and convalescent phases of
ON. Furthermore, visual impairment can be quantiﬁed with
reliable and validated measures of visual function including
high- and low-contrast visual acuity, automated perimetry,
and color vision testing [12–24]. Moreover, damage to the
optic nerve causes atrophy of the RNFL, which can be
measured and quantiﬁed with ocular imaging techniques,
such as optical coherence tomography (OCT) [12–24]. The
RNFL is the most proximal region of the aﬀerent visual
pathway, and it is a unique CNS structure because it lacks
myelin. Given that the back of the eye represents the front
of the brain, OCT provides noninvasive means to quantify
the structural eﬀects of an inﬂammatory insult to the optic
nerve, which can then be compared to functional outcomes,
to construct a structural-functional paradigm of CNS injury.
For this paradigm to gain acceptance, however, OCT needs
to provide a reliable means of detecting true pathological
changes in the anterior visual pathway, which can be
clearly distinguished from test-retest variability inherent
to the technology. Furthermore, structural changes in the
anterior visual pathway captured with OCT need to show
concordance with other markers of disease activity in MS. As
the data from OCT studies continue to mount, there may be
evidencetosupport the tenabilityofthe ONsystemmodel in
clinical research and, potentially, to establish a role for OCT
i nt h ec a r eo fM Sp a t i e n t s .
4.OpticalCoherenceTomography
Optical coherence tomography (OCT) is a noninvasive, ocu-
lar imaging technique that uses low-coherence interferome-
try to generate in vivo, high-resolution (within 10microns),
cross-sectional imagesoftheRNFLbymeasuring backscatter
of infrared light [7, 25–28]. Early OCT systems employed
a Michelson-type interferometer with a low-coherence-
length, superluminescent diode light source [7]. One arm
of the interferometer directed light onto the sample and
collected the backscattered signal. A second reference arm
had a reﬂecting mirror, which was mechanically controlled
to vary the time delay and measure interference. The use of
a low-coherence-length light source meant that interference
occurred only when the distance traveled by the light in
t h es a m p l ea n dr e f e r e n c ea r m so ft h ei n t e r f e r o m e t e ra r e
matched to within the coherence length [7]. This charac-
teristic allowed echo delays of the light from the tissue to
be measured with temporal accuracy [7]. The data were
processed and displayed as a two-dimensional, false-color
image [7].
5.EarlyOCTStudiesinOpticNeuritis:
Breaking New Ground
The ﬁrst study to investigate the role of OCT technology in
the evaluation of MS patients was reported by Parisi [12],
who used an early generation of OCT to compare RNFL
values between 14 MS patients with prior ON and 14 age-
matched controls. The thickness of the RNFL was 46% lower
in MS eyesrelative to controleyes (P<. 01)and28%lowerin
ON eyes as compared to unaﬀected eyes of the same patient
(non-NON eyes) (P<. 01) [7, 12]. In this paper, it was not
clear whether patients had recurrent ON events, which may
have contributedto the robust diﬀerences in RNFL thickness
between ON eyes, non-ON eyes, and control eyes. Yet, even
in the absence of known ON, RNFL values were 26% lower
in MS eyes as compared to control eyes, which suggested
that RNFL damage occurred independent of clinically overt
ON in MS patients [7, 12]. Parisi’s innovative work set the
stage for followup studies, which would further delineate
how changes in RNFL integrity are inﬂuenced by ON and
illustrate how axonal changes in the anterior visual pathway
mirror global CNS damage MS patients.
Inasubsequentstudy,Tripandcolleagues[13]compar ed
RNFL values between 25 ON patients and 15 healthy con-
trols. Optic neuritis patients were recruited with a selection
bias towards incomplete visual recovery. Retinal nerve ﬁber
layer thickness was signiﬁcantly reduced (33%) in ON eyes
(68.7μm) (P<. 001) relative to control eyes (102.9μm)
and in ON eyes (27%) (P<. 001) relative to non-ON eyes
(94.6μm) [13]. Retinal nerve ﬁber layer atrophy was associ-
atedwithlowerVEP amplitudes,worselogMARvisualacuityMultiple Sclerosis International 3
scores, reduced visual ﬁeld mean deviation, and decreased
color vision in ON patients [13]. This intriguing study
further expanded our understanding of OCT by showing
that, in addition to RNFL thickness, macular volumes were
signiﬁcantly reduced after ON in patients with incomplete
visualrecovery.Morespeciﬁcally,macularvolumeswere11%
in lower ON eyes as compared to control eyes (P<. 001) and
9%lowerinONeyesrelativetonon-ONeyes(P<. 001)[13].
In a more recent study, Burkholder et al. [14]f u r t h e r
explored how inner and outer macular volumes related to
RNFLthicknessand visual functionin530MSpatients(with
and without ON) and 111 control eyes. Lower macular
volumes were associated with RNFL thinning, such that
a 10-μmd i ﬀerence in RNFL thickness corresponded to
0.20mm3 reduction in total macular volume [14]. Correla-
tions between RNFL thickness and inner macular volume
were signiﬁcant (r = 0.58, P<. 001), particularly in ON
eyes relative to non-ON eyes (r = 0.61 versus r = 0.50)
in MS patients [14]. These ﬁndings were signiﬁcant because
the ganglion cell layer comprises 34% of the total average
macular thickness [14]; thus, tracking macular volumes
in ON patients may help determine the temporal relation
between primary neuronal cell death and axonal loss after
a CNS inﬂammatory event.
Fisher and colleagues [20]u s e dO C Tt oc o m p a r eR N F L
valuesbetween90MSpatientsand36controlsubjects.While
median Snellen acuity equivalents were better than 20/20
in both groups, mean RNFL thickness was reduced in MS
patients (92μm) relative to controls (105μm) (P<. 001)
with the lowest values noted in the ON eyes (85μm) of
MS patients (P<. 001) [20]. Lower visual function scores
were associated with reduced average overall RNFLthickness
in MS patients, such that, for every 1-line decrease in low-
contrast letter acuity or contrast sensitivity score, the mean
RNFL thickness decreased by 4μm[ 20]. The ﬁndings of this
study suggested a role for OCTas a structural biomarker and
potential secondary outcome measure in future MS clinical
trials.
In 2006 [15], we reported the ﬁndings from 54 patients
who were followed for a mean period of 13 months to
determine whether the extent of RNFL thinning predicted
visual recovery after acute ON. After a year, 74% of
ON patients manifested signiﬁcant RNFL atrophy in their
aﬀected eyes, with most RNFL loss occurring within 3 to 6
months of the ON event [15]. Average RNFL values were
l o w e ri nO Ne y e s( 7 8μm) relative to non-ON eyes (100μm)
(P<. 0001) [15]. Subclinical ON was detected in four
patients during the course of the study [15]. These patients
didnotreportahistory ofpainorvision loss,butophthalmic
testing showed a new visual ﬁeld deﬁcit, an abnormal visual-
evoked potential (VEP) result, the evolution of optic disc
pallor, and newly detected thinning of the RNFL to support
the diagnosis of subclinical ON. By using regression analysis,
weshowed thattherewasalinearrelationship betweenRNFL
thickness and visual ﬁeld mean deviation after ON, such
that, below a “cutoﬀ”o f7 5μm, every 10μmd r o pi nR N F L
was associated with a 6.46dB decrease in mean sensitivity
[15]. Our observations suggested that visual function may
be relatively well preserved after ON until a critical threshold
of axonal integrity is violated; after which, permanent vision
loss is more likely to ensue.
Klistorner and colleagues [16] later evaluated 32 patients
with unilateral ON and 25 control subjects with multifocal
VEP (mfVEP) testing and OCT. The mean RNFL thickness
in ON eyes (85μm) was reduced by 19.2% compared with
control eyes (104μm) (P<. 0001) [16]. There was a 39.8%
reduction in the amplitude of the mfVEP in ON eyes
relative to control eyes (P<. 0001) [16]. Linear regression
analysis demonstrated a strong correlation between inter-eye
asymmetry values of RNFL thickness and mfVEP amplitude
(r = 0.90, P<. 0001). Lower RNFL values were also
associated with increased mfVEP latency (r =− 0.66,
P<. 002) [16]. In addition to demonstrating the utility of
mfVEP in tracking optic nerve injury in ON patients, this
study further conﬁrmed the signiﬁcant correlations between
structural and functional measures of optic nerve integrity
and showed that demyelination contributes to axonal loss in
the anterior visual pathway.
6.RetinalNerve FiberLayerAtrophy:
The Impact ofRecurrentOpticNeuritis
After an isolated ON event, RNFL values decrease by
approximately 20% when patients are recruited without
selection bias [7, 15–20, 24, 29]. For eyes aﬀected by two
or more ON events, however, RNFL atrophy tends to be
more severe [23, 30] and the corresponding impact on visual
function, more dire. In a recent study of 193 MS patients,
we compared RNFL values between 29 eyes aﬀected by two
or more ON events (recurrent ON eyes), 125 eyes aﬀected
by a single ON event (single ON eyes), and 232 non-ON
eyes [23]. Retinal nerve ﬁber layer values were signiﬁcantly
lower in recurrent ON eyes (64.2μm) relative to single ON
eyes (86.3μm)( P<. 0001) and non-ON eyes (100.1μm)
(P<. 0001) [23]. Retinal nerve ﬁber layer atrophy was also
signiﬁcantly worse in single ON eyes as compared to non-
ON eyes (P<. 0001) [23]. Similarly, Yeh and colleagues [30]
noted thataverageRNFLthicknessdecreased with increasing
number of episodes of ON in pediatric patients. These
ﬁndings indicate that recurrent inﬂammatory events have
a cumulative impact and erode axonal integrity in the CNS.
The detection of new RNFL atrophy after ON can be
more challenging in patients with prior ON as compared
to patients experiencing their ﬁrst ON event. Robust inter-
eye diﬀerences in RNFL thickness may be observed for
a CIS patient presenting with unilateral ON, because the
anterior visual pathway has presumably been unscathed
by prior inﬂammation. In contrast, a patient with RRMS
may manifest less apparent inter-eye diﬀerences in RNFL
thickness (Figure 1) and macular volume after ON if there
has been previous optic nerve damage in the contralateral
eye. Similarly, a patient with a new ON event and a prior
history of ON in the same eye may show little change in
R N F Lt h i c k n e s so v e rt i m e ,b e c a u s ei ti sd i ﬃcult to detect
new RNFL thinning super imposed upon preexisting RNFL
atrophy. Given the inherent heterogeneity of MS cohorts
and the predilection for clinical and subclinical ON in4 Multiple Sclerosis International
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(f) Spectral Domain OCT
Figure 1: Case: A 26-year old woman with MS presented with a 2-month history of vision loss in both eyes. Best-corrected visual acuity
was 20/150 in the right eye and count ﬁngers (at 2 feet) in the left eye. There was a left relative aﬀerent pupil defect. Fundus examination
showed mild temporal pallor in the right (a) and left (b) eyes. Spectral domain OCT (c) showed that global average RNFL measurements
were within normal limits in the right eye (OD) (87μm) and the left eye (OS) (90μm). There was relative temporal RNFL thinning in the
left eye (arrow).Two anda halfmonths later, the patient’s visualacuity improved to 20/20 in both eyes, albeit with mildresidual colorvision
deﬁcits. There was more obvious temporal pallor in the right (d) and left (e) eyes. Repeat SD-OCT testing (f) showed progressive global
average RNFL atrophy in the right (OD) (76μm) and left (OS) eyes (75μm).
this disease, caution is needed in the interpretation of RNFL
values, particularly in cross-sectional studies.
7.DeﬁningtheWindowofAxonLossafterAcute
ON: Designing FutureClinicalTrials
Only a few prospective studies have tried to deﬁne the
time interval during which RNFL atrophy progresses after
acute ON [17, 21, 24]. Establishing a potential therapeutic
“window” is important for the design of future trials
employing OCT as an outcome measure in ON patients.
Noval and colleagues [21] followed 12 patients with acute
ON and observed an initial increase in RNFL thickness,
which resolved by 1.5 months. In ON eyes, they reported
a 25% reduction in RNFL thickness at 6 months [21]. In
2008, we followed 78 ON patients over a mean period of 28
months and observed that the earliest signiﬁcant diﬀerence
in RNFL thickness between ON eyes and non-ON eyes
manifested after two months, in the temporal RNFL region6 Multiple Sclerosis International
(inter-eye diﬀerence = 12.5μm, P = .005) [17]. In a subset
of20 patients who underwent regular OCTtesting overa 12-
month period, we reported that RNFL thinning progressed
up to 6 months after acute ON and stabilized thereafter
[17].Similarly,inarecentlongitudinalstudy,Hendersonand
colleagues [24] evaluated 23 patients with acute unilateral
ON with serial OCT testing at presentation and after 3, 6, 12,
and18monthsoffollowup.Twelvecontrolsubjectswerealso
imaged, on two occasions, a median of 552 days (range 350–
907 days) apart [24]. Retinal nerve ﬁber layer values were
signiﬁcantly increased in ON eyes relative to non-ON eyes
at baseline but then signiﬁcantly decreased at all later time
points [24]. Visual recovery at 12 months was not related to
the extent of RNFL swelling seen acutely but was associated
with the amount of RNFL loss observed in ON eyes [24].
As was noted in previous studies, the authors concluded that
RNFLthinningisusuallyevidentwithin3monthsofanacute
ON eventand that OCT-measured RNFL loss after 6 months
isa tenableoutcomemeasure for neuroprotectiontrials [24].
Given the small patient numbers included in the afore-
mentioned studies, caution must again be exercised when
interpreting the collective results. Our study included only
78 ON patients, and there was variability in followup across
testing intervals [17]. To determine the time required for
RNFL atrophy to stabilize within 12 months of an acute
ON event, we tracked RNFL changes in a subset of 20
patients at regular intervals over a one-year period [17].
Our study lacked a control group, which further limited
our conclusions [17]. Similarly, for the 23 ON patients and
12 control subjects studied by Henderson and colleagues
there was some variability in followup [24]. It was also
noteworthy that in ON eyes RNFL values ranged from 87 to
281μm (median 117μm, mean 133μm) at baseline, and two
patients had initial RNFL values exceeding 200μm. Retinal
nerve ﬁber layer values equal to or greater than 250μma r e
atypical in ON, because the extent of optic disc edema tends
to be relatively mild relative to other optic neuropathies
associated with more severe optic disc swelling (i.e., anterior
ischemic optic neuropathy). When a patient population size
is limited, it is unclear how outliers impact the overall
interpretation of results, even in the context of an elegantly
designed study. Therefore, further controlled, prospective
clinical trials involving a larger numbers of patients will be
neededtoﬁrmly establishtheoptimal time“window” to trial
new therapeutic strategies in ON patients.
8.OpticalCoherenceTomography: Riskof
MultipleSclerosisafterOpticNeuritis
Onlytwopriorstudieshaveexploredtheassociationbetween
RNFL atrophy and future risk of MS in ON patients,
and the data were largely negative [18, 31]. Previously,
we compared RNFL values in ON eyes and non-ON eyes
between patients who developed CDMS (42%) and those
that did not developMS 24 months after an ON event(58%)
[18]. Mean RNFL values were lower in ON eyes of non-
MS patients as compared to CDMS ON eyes after one year
(P = .05) due to more severe ON events in the former
[18]. Temporal RNFL values were lower in the non-ON
eyes of CDMS patients, but the results were not statistically
signiﬁcant (P = .13) [18]. From our ﬁndings, we concluded
that RNFL thickness did not reliably distinguish patients
at higher risk of converting to CDMS after ON. Similarly,
Outteryck and colleagues [31] performed OCT testing on 56
CIS patients (18 with optic neuritis and 38 without optic
neuritis) and 32 control subjects, to investigate whether
measures of RNFL thickness and macular volume revealed
early retinal axonal loss. In this prospective case series, there
was no link between RNFL and (1) MRI evidence of dissem-
inated CNS inﬂammation at baseline, (2) disseminated CNS
inﬂammation according to the revised McDonald criteria,
(3) gadolinium enhancement on initial MRI, (4) multifocal
CIS presentation, (5) altered visual evoked potentials, or (6)
development of “McDonald-” proven MS at 6 months [31].
Furthermore, patients who developed CDMS (n = 13) or
McDonald-criteria proven MS (n = 23) did not have more
severe RNFL atrophy [31]. These investigators concluded
that OCT does not predict conversion to MS at 6 months in
CIS patients and postulated that conversion to MS after ON
is more likelyinﬂuencedby inﬂammatory eventsthan axonal
degeneration.
9.OpticalCoherenceTomographyStudiesin
PediatricOpticNeuritisPatients
Multifocal CNS demyelination has been reported to occur
in approximately 0.4 per 100,000 of the pediatric patient
population[30].Similartoadults,ONisarelativelycommon
occurrence in pediatric patients such that 22% of children
experience ON as their ﬁrst demyelinating event and 35%
of children who eventually develop MS experienced ON
during their ﬁrst clinical episode [30]. In a recent pediatric
ON study, Wilejto and colleagues [32] reported unilateral
optic nerve involvement in the majority (58%) of pediatric
patients (n = 36). Visual recovery after ON was considered
complete in 39 of 47 aﬀected eyes (83%) [32]. Cranial MRI
scans demonstrated white matter lesions separate from the
optic nerves in 54% of children. In this study, the risk of MS
was 36% at 2 years, and bilateral ON was associated with a
greater future risk of MS [32]. Clinical ﬁndings extrinsic to
the visual system on baseline examination and MRI evidence
ofwhite matterlesions outsidethe opticnerveswere strongly
associated with a future diagnosis of MS [32]. Yeh and
colleagues [30] used OCT in a cross-sectional study of 38
consecutive children (age <18 years) who had at least one
documented clinical episode of an acquired demyelinating
event and two control groups, including (1) 15 normal
healthy children (30 eyes) with no history of neurological or
other chronic disease and (2) 5 children (10 eyes) with other
nondemyelinating disorders (OND), including headache,
attention deﬁcit hyperactivity disorder, and depression [30].
In MS patients RNFL thickness was 99μmi nn o n - O Ne y e s
and 83μm in ON eyes. Children with acute disseminated
encephalomyelitis (ADEM) and transverse myelitis (TM)
had lower RNFL values in ON eyes (67μm) relative to non-
ON eyes (102μm) [30]. Macular volumes were markedly
lowerinONeyesofchildrenwith ADEM/TM(6.2mm3)and
chronic relapsing inﬂammatory optic neuropathy (CRION)Multiple Sclerosis International 7
(6.0mm3), suggesting a more widespread disease process
in these clinical entities [30]. All subgroups with a clinical
history of ON had lower average RNFL values (83μmf o r
MS patients; 67μmf o rA D E M / T Mp a t i e n t s ;8 9μmf o rC I S
patients; 50μm forCRIONpatients)than controls(107μm).
Diﬀerencesbetween childrenwith demyelinating disease and
controlsand between ONand non-ON eyes were statistically
signiﬁcant (P<. 001). On the basis of their ﬁndings, the
investigators concluded that OCT may be a valuable tool for
monitoring anterior optic pathway dysfunction in children
with demyelinating diseases.
10.OpticalCoherenceTomography
andNeuromyelitisOptica
Neuromyelitis optica (NMO) is a severe inﬂammatory
p r o c e s so ft h eo p t i cn e r v e sa n ds p i n a lc o r da n di sa s s o c i a t e d
with poor clinical recovery [33–38]. There have been several
studies which have explored the role of OCT in quantifying
the extent of axonal damage in the anterior visual pathway
secondary to NMO with a view to distinguishing the ON
associated with this clinical syndrome [36–38]. Naismith
[36] used OCT to study 22 subjects with NMO or NMO
spectrum disorders and 47 MS patients. In ON eyes, NMO
was associated with lower RNFL values compared to MS,
when controlling for visual acuity (57μmv e r s u s6 7 μm;
P = .01) or for contrast sensitivity (61μmv e r s u s7 0 μm;
P = .02). The superior and inferior quadrants were more
severely aﬀected in NMO than MS eyes. These authors noted
that the odds of falling into the NMO group increased by
8% for every 1μmd e c r e a s ei nR N F Lt h i c k n e s s[ 36]. Similar
ﬁndings were noted by Ratchford and colleagues [37]w h o
usedOCTtostudy26NMOspectrum patientswithahistory
of ON, 17 patients with isolated longitudinally extensive
transverse myelitis (LETM) without ON, 378 patients with
RRMS,and 77 healthy controls. These investigators observed
signiﬁcant RNFL thinning in NMO ON eyes (63.6μm)
r e l a t i v et oR R M SO Ney e s( 8 8 . 3μm) (P<. 0001) and control
eyes (102.4μm) (P<. 0001). A ﬁrst episode of ON was
estimated to cause 24μm more loss of RNFL thickness in
NMO than RRMS eyes[37]. In a third study, Nakamura[38]
e v a l u a t e d3 5e y e so f1 8p a t i e n t sw i t ht h e“ N M Os p e c t r u m ”
and 14 MS patients to determine whether RNFL thickness
correlated with the clinical presentation in patients with
NMO and ascertain what clinical factors lead to poor visual
outcomes. Overall RNFL measurements were thinner in
N M OO Ne y e st h a nM SO Ne y e s( 6 4 μmv e r s u s8 4 μm;
P = .0006) especially in the superior and inferior RNFL
quadrants [38]. Mean RNFL negatively correlated with the
number of relapses in the NMO group. A receiver operating
characteristic (ROC) analysis showed that the overall RNFL
“cutoﬀ” value for decreased visual acuity (measuring less
than 20/20) was 71μmi nt h eN M Og r o u p[ 38]. The
frequency of the ON relapses and the time to initiate
treatment with high-dose intravenous methylprednisolone
signiﬁcantly aﬀected the preservation of RNFL thickness in
this study [38]. Hence, the studies to date suggest that OCT
may be used to distinguish anterior visual axis involvement
in NMO from ON associated with MS.
11.ConclusionsandFutureDirections
Recent technological innovations have introduced the era
of “Fourier” or “Spectral” domain OCT (SD-OCT). In this
new generation of the device, all light echoes are detected
simultaneously, leading to a dramatic increase in sensitivity
that enables high-speed imaging [7]. Spectral domain OCT
is now commercially available and provides an axial image
resolution of 5–7μm, with imaging speeds of 25,000 axial
scans per second. This imaging speed is approximately
50 times faster than the previous generations of OCT
technology [7]. Retinal nerve ﬁber layer measurements in
MS patients diﬀer considerably between TD-OCT and SD-
OCT devices, with excellent correlations between values
obtained from both imaging techniques [39–43]. Recently,
Bock and colleagues [39] compared SD-OCT and TD-OCT
imaging techniques in 55 MS patients and reported a strong
correlation (Pearson’s r = 0.926, P<. 001) between the two
technologies. There were, however, signiﬁcant diﬀerences
in the absolute RNFL measurements (mean ± standard
deviation 8.1μm ± 6.2, range −12 to 23μm), and therefore
the results from the two devices were not interchangeable.
The ﬁndings of this study were similar to those reported
by Knight et al. [42] who compared SD-OCT and TD-
OCT RNFL values in glaucomatous patients. In both stud-
ies, SD-OCT tended to measure “more thinly” than TD-
OCT at higher RNFL values, whereas, for thinner RNFL
values, SD-OCT measured “more thickly” than TD-OCT
[39].
The reproducibility of SD-OCT retinal measurements
relative to TD-OCT has recently been evaluated in MS
and glaucoma patients. In a prospective study of 58 MS
patients and 32 healthy controls, SD-OCT testing was
performed to determine optimal intervisit, interrater, and
intrarater reproducibility [41]. The authors noted excel-
lent reproducibility of average and quadrant RNFL values,
average macular thickness, and total macular volumes [41].
Leung and colleagues [40] evaluated RNFL measurement
variability, diagnostic sensitivity and speciﬁcity, and the
strength of the structure-function association obtained with
SD-OCT versus TD-OCT in a prospective, cross-sectional
study of 97 healthy controls and 83 glaucoma patients. The
intra-visit repeatability of SD-OCT ranged between 5.12
and 15.02μm and the intervisit reproducibility, between
4.31 and 22.01μm. Overall, SD-OCT demonstrated lower
measurement variability compared with TD-OCT. Finally,
in a prospective observational study of 110 eyes, retinal
measurements were compared between six diﬀerent TD-
OCT and SD-OCT devices including Stratus and Cirrus
(Carl Zeiss Meditec, Inc.), Spectralis HRA + OCT (Hei-
delberg Engineering), RTVue-100 (Optovue Inc.), SDOCT
Copernicus HR (Optopol Technology S.A.), and 3D OCT-
1000 (Topcon Corporation) [43]. The standard analysis
protocols for macular thickness evaluation were evaluated
with each instrument. The six diﬀerent devices produced
measurements that diﬀered in variance (Bartlett test, P =
.006), and mean values (Friedman test, P<. 001) [43].
Bland-Altman analyses showed that the limits of agree-
ment for all the comparisons were not acceptable, and8 Multiple Sclerosis International
regression analysis revealed high standard error values
[43]. The ﬁndings of this study indicated that retinal
thickness measurements obtained with various OCT devices
were diﬀerent beyond clinical practice tolerance. The dif-
ferences between devices were attributed to the analysis
algorithms used to set retinal inner and outer boundaries
[43].
Thus, while innovations in OCT technology oﬀer poten-
tial advantages including minimizing error and improving
test-retest reliability in the evaluation of MS patients,
challenges remain. With each new reincarnation of the tech-
nology, there is a disruption in the collection of longitudinal
data, which is vital in the management of a chronic disease.
Furthermore, as the ﬁrst SD-OCT studies are beginning to
emerge, it is debatable whether any of these early reports
have taught us anything that we did not already know
regarding the potential role for OCT in the management
of ON and MS patients. As the technology continues to
advance,itisimperativethattheresultsofOCTstudiesprove
to be clinically relevant, not simply statistically signiﬁcant
to meaningfully impact our understanding and treatment of
disease. In the context ofMS, the challenge remains to deﬁne
the amount of RNFL “signal” that represents pathology,
and to distinguish this from the “noise” of the technology.
This task may be onerous given the heterogeneity of MS
cohorts and the prevalence subclinical disease activity in
this patient population. On a practical level, MS patients
may develop other occult ocular conditions (i.e., age-related
maculardegenerationandglaucoma)thatdamagetheretinal
architecture, making the interpretation of RNFL atrophy
diﬃcult. Also, retrograde transsynaptic retinal ganglion cell
degeneration due to MS lesions within the posterior optic
pathways has been shown to cause RNFL atrophy [44].
Thus, in the evaluation of RNFL thickness, it may also be
necessary to distinguish the eﬀects of postgeniculate lesions
from subclinical disease in the anterior visual pathway in MS
patients.
In conclusion, there is increasing evidence to suggest
a role for OCT in the evaluation of ON and MS patients.
Optical coherence tomography may complement our exist-
ing arsenal of tools including tests of visual function,
neuroimaging techniques, and electrophysiological studies
and help develop a structural-functional paradigm of CNS
inﬂammation. Furthermore, OCT may be used to capture
structural changes in the anterior visual pathway, which will
provide unique insights regarding pathogenic mechanisms
of CNS injury and, in turn, to develop more eﬀective
therapeutic strategies for MS patients. Future longitudinal,
large-scale studies will be needed to ultimately determine
how this technology can be optimally implemented in
aresearchsetting,withtheultimategoalofenhancingpatient
care.
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